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Eosinophils are bi-lobed, multi-functional innate immune cells with diverse cell surface 
receptors that regulate local immune and inflammatory responses. Several inflammatory and 
infectious diseases are triggered with their build up in the blood and tissues. The mobilization 
of eosinophils into the lungs is regulated by a cascade of processes guided by Th2 cytokine 
generating T-cells. Recruitment of eosinophils essentially leads to a characteristic immune 
response followed by airway hyperresponsiveness and remodelling, which are hallmarks of 
chronic respiratory diseases. By analysing the dynamic interactions of eosinophils with their 
extracellular environment, which also involve signalling molecules and tissues, various 
therapies have been invented and developed to target respiratory diseases. Having entered 
clinical testing, several eosinophil targeting therapeutic agents have shown much promise and 
have further bridged the gap between theory and practice. Moreover, researchers now have a 
clearer understanding of the roles and mechanisms of eosinophils. These factors have 
successfully assisted molecular biologists to block specific pathways in the growth, migration 
and activation of eosinophils. The primary purpose of this review is to provide an overview 
of the eosinophil biology with a special emphasis on potential pharmacotherapeutic targets. 
The review also summarizes promising eosinophil-targeting agents, along with their 
mechanisms and rationale for use, including those in developmental pipeline, in clinical 
trials, or approved for other respiratory disorders. 
 































1.0  Introduction  
 
1.1 Role of eosinophils in host defense and immunity  
 In 1879, Paul Ehrlich was the first person to recognize the unique ability of 
eosinophils to stain using acidophilic dyes (1). For many years, they were recognized as cells 
with end-stage effector functions in helminth infections and tissue damage (1). However, the 
plethora of clinical studies carried out in previous years have helped establish the crucial role 
of eosinophils in host defense, allergic inflammation, innate and adaptive immunity (1,2). 
Importantly, the interaction of eosinophils with B-cells allows them to process antigens, 
stimulate T-cells and induce humoral responses (1). Inflammatory and adaptive responses can 
also be initiated by eosinophils through their bidirectional interactions with dendritic cells 
(DCs) and T-cells (3). Activated eosinophils are able to release a large assortment of newly 
synthesized as well as pre-formed mediators, such as cytotoxic granule proteins, cytokines, 
chemokines, and lipid mediators which contributes to the various activities of eosinophils in 
inflammatory and infectious responses (4).  
Eosinophils are now recognized as regulatory cells with the proven ability to 
influence and enhance local inflammation, instead of just simply effector granulocytes with 
cytotoxic activities (5). The immunomodulatory role played by eosinophils include mediating 
aluminum hydroxide-induced B-cell priming, acting as an antigen-presenting cell (APC) for 
T-cells, influencing T-cell differentiation (i.e. Th1 or Th2), and recruiting T-cells, DCs and 
macrophages to inflammatory sites in the host (6,7). Eosinophils were shown to regulate DCs 
and Th2 pulmonary immune response following an allergen challenge in mouse models (8). 
Moreover, a unique function of eosinophil is the suppression of DC-mediated Th17 
production (8). Thus, eosinophils are important modulatory cells to maintain the equilibrium 
between DC-mediated Th2 and Th17 signaling pathways following an allergen exposure and 
subsequently, the allergic airway inflammation progression (8). Recently, it was discovered 
that eosinophils are necessary for the long-term preservation of plasma cells in the bone 
marrow and eosinophil depletion induces bone marrow plasma cells apoptosis (9). Wu et al., 
also reported that eosinophils regulate glucose homeostasis by preserving adipose tissue 
alternatively-activated macrophages (AAMs) via the secretion of IL-4 cytokine (10). As a 
regulator of innate immune response, eosinophils are also responsible for apoptotic cell 











 Similar to other granulocytes, eosinophils undergo development and differentiation in 
the bone marrow (12). Upon maturation, eosinophils are distributed in various organs in the 
body, such as blood, lung, uterus, thymus, spleen, mammary gland, adipose tissue, and 
gastrointestinal tract (GI), to carry out their physiological functions under homeostasis (6,12). 
The recruitment of mature eosinophils from the systemic circulation to the inflammatory sites 
occurs following the overexpression of eosinophil-specific chemokines in response to stimuli 
(12). Interleukin-5 (IL-5) is the most important cytokine responsible for eosinophil 
differentiation, priming and survival and its main sources of production are type 2 T-helper 
(Th2) cells and type 2 innate helper lymphoid cells (ILC2) (6,12).  
 
1.2 Cytokines, chemokines, receptors, and surface markers 
 A broad variety of cytokines, lipid mediators and other major molecules are expressed 
and secreted by eosinophils (Figure 1). These molecules are stored in eosinophilic granules 
and rapidly secreted in response of a specific stimuli, hence altering the external 
microenvironment and cellular functions. Eosinophils are distinguished from other 
lymphocytes, such as T-cells and B-cells, due to their ability to store and rapidly release pre-
formed cytokines within minutes in response to stimuli (13,14). Besides pre-formed 
cytokines, eosinophils can carry out de novo synthesis and secretion of other immunological 
factors (14). It was hypothesized that the binding of soluble N-ethylmaleimide sensitive 
factor attachment protein receptors (SNARES), which are part of the membrane fusion 
complexes, regulates the final steps of cytokine secretion from eosinophilic crystalloid 
granules and secretory vesicles (14).  
Eosinophils are a major source of IL-5 cytokine, which is important for its differentiation, 
survival and chemotaxis (15). Other Th2 immunomodulatory cytokines secreted by 
eosinophils include IL-4 and IL-13 (13). Besides Th2 cytokines, other cytokines with Th1 
and regulatory capacities released by eosinophils include IL-6, IL-10, IL-12, TNF-α, TGF- , 
and IFN-γ (13). IL-6, IFN-γ, and TNF-α causes tissue damage through their pro-
inflammatory actions whereas TGF-  contributes to airway remodeling via its role in 
epithelial changes, subepithelial fibrosis and microvascular changes (16,17). As for the lipid 
mediators, eosinophils releases a large quantity of prostaglandins, leukotrienes, and platelet-
activating factors (PAF) (16). Eosinophils express a wide variety of receptors and molecular 
surface markers on their cell surfaces, including IL-5R , prostaglandins (CRTH2), CC-











leukotriene B4 receptors (IL-4R, IL-5R, IL-33R, IFN-γR, TGF-βR, CCR1, CCR3, CCR4, 
and TSLPR), PAF-receptor, FcαR, FcγR, and pattern-recognition receptors (PRRs) (18). The 
most prominent cytokine receptor present on human and mice eosinophils is IL-5R  where 
the main receptors which define the distinct biology of eosinophils are CCR3 and SIGLEC-8 
(19). Human eosinophils uniquely express SIGLEC-8 and the binding of antibodies or glycan 
ligands with this structure leads to apoptosis of eosinophils (20). The PRRs families 
expressed by human eosinophils include Toll-like receptor (TLR) family (TLR1-5, TLR7, 
TLR9), C-type lectin receptor (CLR) (Dectin-1), nucleotide-binding oligomerization domain 
(NOD)-like receptors (NOD1, NOD2), and receptors for advanced glycation end-products 
(RAGE) (19,21,22). Interaction with eosinophilic PRRs induces eosinophil survival, 
oxidative burst, adhesion system activation, and mediator release (21).  
 Integrins are cell surface proteins commonly found on immune cells which functions 
to merge the intracellular and extracellular domains of the immune system. Eosinophils 
express several integrins, such as α4β1 (CD49d/CD29), α6β1 (CD49f/ CD29), αLβ2 
(CD11a/CD18), αMβ2 (CD11b/CD18), αXβ2 (CD11c/CD18), αDβ2, and α4β7 (23). These 
integrins interact with not only their respective ligands, but also vascular adhesion molecule 1 
(VCAM-1), intracellular adhesion molecule 1 (ICAM-1), periostin, laminin, and fibronectin 
located in the extracellular matrix or other cells (23).  
 Furthermore, blood eosinophils constitutively expresses selectins, including P-selectin 
glycoprotein ligand-1 (PSGL-1, CD162) and L-selectin (CD62L) (24). A high level of 
surface P-selectin results in eosinophilic β1 integrin activation in vivo and thus, stimulates 
eosinophilic adhesion to VCAM-1 and migration to the airway (24).  
Notch receptors and Notch ligands are also expressed on human blood eosinophils, 
which serve as important components for eosinophil autoregulation (25). A study showed that 
granulocyte-macrophage colony-stimulating factor (GM-CSF) influences the expression and 
activation of Notch molecules and thus, affects the activity and survival of eosinophils (25).  
 
1.3 Eosinophilic granule proteins  
 Eosinophils store pre-formed enzymatic and non-enzymatic cationic proteins in large 
secondary granules which are selectively secreted in response to specific stimuli (26). The 
release of these granule proteins have typically be considered as the primary effector 
mechanism of eosinophils against specific parasites and in allergic inflammation (27). The 
antibacterial effect of eosinophils in vivo is specifically mediated thorough the release of 











granules containing cationic proteins distinguishes eosinophils from other leukocytes (29). 
The four notable granule proteins present in human eosinophils include eosinophil peroxidase 
(EPO), major basic protein (MBP), and eosinophil-associated RNases (EARs) which are 
eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) (19,29).  
 EPO is the cationic protein present most abundantly in the matrix of the crystalloid 
granules (16). EPO contributes to eosinophil function by generating reactive oxidizing 
species (ROS) as well as acting as a direct toxin against mammalian cells and parasites (16). 
The promotion of oxidative stress by EPO results in cell apoptosis and necrosis (19,30). A 
study carried out by Panagopoulos et al., reported that EPO and other peroxidases play a part 
in angiogenesis in addition to cellular proliferation, migration, and invasion (31). Ochkur et 
al., also demonstrated the use of a sensitive and specific ELISA for the detection of EPO 
(32).  
MBP exerts direct toxicity which contributes to its function in altering membrane 
permeability and enzyme functions in mammalian cells, microbes, and helminths (16,19). As 
for its role in the pathophysiology of asthma, MBP induces bronchoconstriction and epithelial 
tissue damage (16). MBP was also reported to have pro-angiogenic effects in vitro and in 
vivo (33).  
ECP and EDN are part of the ribonuclease A superfamily (16). EDN demonstrates 
cytotoxicity, neurotoxicity, and antiviral activity (single-stranded RNA virus), but it exerts 
low toxicity towards mammalian cells and parasites (16). Tsuda et al., recently reported that 
EDN stimulates matrix metalloproteinase 9 (MMP-9) production from nasal epithelium, thus 
indicating its potential role in the pathogenesis of eosinophilic chronic rhinosinusitis (ECRS) 
(34). Conversely, ECP shows distinct toxicity towards a large variety of bacteria, helminths, 
single-stranded RNA viruses, and host tissues (16). ECP exerts its toxic effects through 
formation of pores in target membranes (19). Besides its cytotoxic effects, ECP also 
stimulates airway mucus hypersecretion and mast cell degranulation, as well as suppresses B-
cell immunoglobulin synthesis and T-cell proliferative responses (19). EDN is known to 
possess multifunctional properties and may contribute to innate immunity by either killing or 
inactivating viral invaders (35). In 1998, the potential of EDN as an antiviral agent against 
respiratory syncytial virus was demonstrated under in-vitro settings (36). Domachowske and 
colleagues demonstrated a dose-dependent decline in the infectivity of respiratory syncytial 
virus B after the introduction of eosinophils into the viral suspension (36). Interestingly, the 
inclusion of ribonuclease inhibitor was found to reverse the antiviral effect observed by 











antiviral role of EDN was confirmed when a 40-fold decrease in infectivity, after the 
introduction of EDN into the suspension of respiratory syncytial virus B was obtained. 
Importantly, the inactivated form of EDN was reported to have no antiviral effects. 
Furthermore, the observed antiviral activity of EDN was found to be the direct 
ribonucleolytic destruction of extracellular virions. These findings collectively suggest that 
EDN may also be used as a therapeutic agent for the management of respiratory syncytial 
virus (36). Furthermore, Rugeles et al., reported that EDN was responsible for the majority of 
anti-HIV-1 activity shown by alloantigen-stimulated factors in the supernatant of mixed 
lymphocyte reactions (37). 
 
Additionally, another important protein found in primary granules of eosinophils is 
galectin-10, or Charcot-Leyden crystal protein. Galectin-10 was shown to be strongly 
associated with sputum eosinophilia and hence, can function as a potential alternative 
biomarker of eosinophil-associated airway inflammation (38).  
 
1.4 Degranulation  
 The extracellular release of eosinophilic granule proteins is termed as degranulation. 
Piecemeal degranulation (PMD) is generally acknowledged as the most prevalent manner of 
eosinophilic degranulation (16,19) During PMD, the contents of the granule are selectively 
packaged into vesicles which are transported across the cytoplasm and fused with the cell 
membrane in order to extracellularly release the granule proteins at the cell surface (29). 
Cytokines and chemokines which induces PMD are IFN-γ, CCL-11 (eotaxin-1), and TNF-α 
(16,39). Following the release of its granule proteins via PMD, the eosinophil remains fully 
functional and responsive to other stimuli. An example of PMD is the release of IL-4 from 
eosinophils stimulated with eotaxins, whereby secretory vesicles deliver IL-4/IL-4R   
complex, which is initially formed inside the granule membrane, to the cell surface and 
subsequently released into the extracellular space (19). 
Another mechanism of degranulation observed in eosinophils is associated with 
cytolysis, in which the eosinophil undergoes cell lysis in a manner that morphologically 
differs from either apoptosis or necrosis, thus releasing intact, cell-free, membrane-bound 
granule proteins which are fully competent (29). The manner of cell death in eosinophilic 
cytolysis is termed as extracellular trap cell death (ETosis), whereby the nuclear membrane 











acknowledged as a common method for the release and deposition of cell-free eosinophilic 
granules in eosinophil-associated disorders (29). 
Lastly, eosinophil degranulation can also occur by classical exocytosis, in which the 
fusion of intracellular granules with the plasma membrane precedes the extracellular release 
of the total granule contents (40). This mechanism of degranulation does not occur 
commonly in eosinophilic diseases, except in the presence of parasitic helminths or specific 
fungi (40).  
Although degranulation is the primary mechanism in which eosinophils exert their 
function, this process does not occur during transit in blood circulation. Instead, granules are 
commonly released when the eosinophils arrive at the site of inflammation (41).  
 
1.5 Hypereosinophilic syndromes  
 Hypereosinophilic syndromes (HES) comprise of a heterogenous collection of 
disorders with common features of elevated blood and tissue eosinophils and tissue damage 
(42,43). The clinical manifestations are variable and may include any organ system, but most 
commonly the skin (42). Since 1975, the definition of HES includes 3 criteria: (i) blood 
eosinophil count ≥1500/mm
3
 for >6 months (or mortality within 6 months associated with 
signs and symptoms of hypereosinophilic disease), (ii) insufficient evidence of other causes 
of eosinophilia (e.g. parasite, allergy), and (iii) presumptive signs of organ involvement (e.g. 
GI dysfunction, heart failure, central nervous system impairment, weight loss, or fever) (44). 
However, there are several shortcomings with these definitions of HES. Marked eosinophilia 
is typically caused by helminth infections, but other non-infectious causes include 
malignancies, drug reactions, immunologic, allergic and inflammatory diseases (45).  
2.0. Eosinophils and asthma  
 
2.1 Eosinophils in the Pathophysiology of Asthma  
 
2.1.1 Eosinophilic asthma  
Asthma is an inflammatory respiratory disorder outlined by airway 
hyperresponsiveness (AHR), airway obstruction, mucus hypersecretion, airway 
inflammation, tissue damage and airway remodeling (16,46–48). According to a study 
conducted by the Global Burden of Disease (GBD), it was estimated that around 339.4 
million people globally were affected by asthma in 2016 (49). Eosinophils have been closely 
related to the pathophysiology of asthma, as reported from the elevation of eosinophil 











(16,46). In a certain percentage of patients, eosinophilic airway inflammation represents the 
occurrence of bronchial asthma (50). Eosinophils are pro-inflammatory granulocytes with 
major contributions to the inflammatory responses of asthmatic patients, especially in T2-
high asthma phenotypes such as severe eosinophilic asthma, by releasing inflammatory 
mediators to trigger an inflammatory cascade as well as exerting toxic effects directly on host 
tissues (51). Severe asthma is a heterogenous disorder as different phenotypes exists, such as 
eosinophilic asthma. Eosinophilic asthma can be clinically characterized by its severity and 
frequent exacerbations (50). Additionally, other features of eosinophilic asthma includes 
sputum and airway eosinophilia, elevated blood eosinophil count, adult-onset, and 
involvement of nasal polyps-associated chronic rhinosinusitis in 50% of the patients (51,52). 
Conversely, non-eosinophilic asthma can be characterized by low eosinophil counts, with the 
dominant inflammatory cell type being neutrophils and mixed granulocytes, or very few 
inflammatory cells (51). Generally, the higher the degree of eosinophilia, the greater the 
disease severity and exacerbation frequency in eosinophilic asthma (46). Eosinophilic and 
paucigranulocytic asthma (asthma with very few inflammatory cells) are among the dominant 
inflammatory asthma phenotypes.  
 
2.1.2 Eosinophil recruitment, migration, development, and survival 
In eosinophilic asthma, which is also known as Th2 asthma, eosinophils present as the 
hallmark as seen in their elevated numbers (Figure 2) (53). The exposure of airway 
epithelium to allergens or antigens triggers an immunological cascade which attracts 
eosinophils to the airways by Th2 cytokines and chemoattractants (16). Th2 cytokines 
secretion contributes to the increase in eosinophil counts in the BALF as they are responsible 
for eosinophil recruitment, migration and survival (16). The Th2 cytokines which induces 
eosinophil migration to the airways include IL-4, IL-5 and IL-13, which are produced by 
activated Th2 lymphocytes and ILC2s (16,53). Among them, IL-5 and the chemokine 
eotaxin-1 (CCL11) are the primary mediators for the release of bone marrow eosinophils and 
trafficking of eosinophils to the lungs (16,51). Eotaxin is produced by allergen-challenged 
endothelial and epithelial cells and enhances eosinophil migration by binding to CCR3 
expressed on its surface (16). Besides stimulating eosinophil migration, IL-5 is also an 
important mediator of eosinophils differentiation, development, activation and survival 
(52,54). Other major sources of IL-5, other than Th2 cells and ILC2s, are CD34+ progenitor 
cells, mast cells, invariant natural killer (NK) T-cells, and eosinophils themselves (55). In 











circadian cycling (55). IL-4 and IL-13 do not directly mediate eosinophil trafficking; IL-4 
sustains eosinophil migration by inducing B-cell isotype switching to immunoglobulin (Ig)E 
for the development of Th2 lymphocytes whereas  IL-13 stimulates eotaxin production (53). 
IL-4 also induces the expression of VCAM-1 and eotaxin by epithelial cells which enhances 
eosinophil migration to the site of allergic inflammation (16).  study by Beckert et al., 
provides evidence on the effects of the Th2 cytokines, either alone or in combination, on 
eosinophils in a mouse model (56). C57BL/6 mice were intranasally administered equimolar 
amounts of single agent or combination IL-4, IL-5 and IL-13. The results demonstrated that 
IL-4 and IL-13 were correlated with airway eosinophilia, progression of airway 
hyperresponsiveness, and goblet cell metaplasia (56). However, IL-4 demonstrated weaker 
effects than IL-13 and no synergism was observed when these two cytokines were 
administered in combination (56). After the administration of IL-5, it was observed that the 
eosinophil count in bone marrow and lung tissues were increased but no structural changes of 
the eosinophils were observed (56). The combined administration of IL-5 and IL-13 
significantly increased the number of lung, airway, blood and bone marrow eosinophils, 
whereas IL-5 and IL-4 combined only increased eosinophils count in lungs and bone marrow 
(56).  
Besides Th2 cells, the damaged epithelial cells also contributes to eosinophils 
recruitment through the release of IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) 
(16). These cytokines activate ILC2 from the innate immune system to secrete IL-4, IL-5 and 
IL-13 (16). Additionally, IL-33 and granulocyte-macrophage colony-stimulating factor (GM-
CSF) contributes to eosinophils differentiation and migration as well as mediate their survival 
in the airways (16). IL-33 directly stimulates eosinophil differentiation from CD117
+
 
hematopoietic progenitor cells and contributes to the exacerbation of eosinophilic 
inflammation by elevating eosinophil, macrophage, lymphocyte, IL-13, TGF-β, CCL3, 
CCL17, and CCL24 levels in the airways (57). IL-18 was also recently identified as an 





pathogenic eosinophils (54). 
Fanat et al., researched the effects of cells sourced from human airway smooth muscle 
(HASM) on eosinophils (58). In this study, peripheral blood progenitor cells collected from 
atopic asthmatics and control subjects with no atopy were cultured together with supernatant 
collected from HASM cells culture. At the end of the study, it was observed that HASM cell-
derived cytokines stimulated eosinophil differentiation via the p38 mitogen-activated protein 











by HASM cells were identified to be IL-5 and GM-CSF as eosinophil differentiation was 
inhibited by anti-IL-5 and anti-GM-CSF blocking antibodies (58). Thus, the researchers 
concluded that HASM cells have the ability to modulate differentiation and maturation of 
eosinophils from precursor cells including immature eosinophils, that may lead to 
eosinophilic inflammation and airway remodeling in severe asthmatics (58). However, 
haemopoietic progenitor cell migration and adhesive response in vitro are not influenced by 
HASM cells. (58).  
Lung dendritic cell (DC) subsets also play a role in initial eosinophil recruitment to 
the site of allergen challenge. A specific sub-type of DCs in the lung, i.e., CD24CD11b 
DC2s, produce NO synthase which induces CCL17 and CCL22 on lung cDC1s to attract 
eosinophils for initial eosinophil infiltration. After the allergen challenge, eosinophil 
recruitment is inhibited by lung CD24 cDC2s through TGF-β1 secretion (59). Hence, the 
impaired expression of CCL17 and CCL22 lead to the response seen during the late phase 
reaction. It was suggested that different lung APCs secrete specific soluble factors during the 
memory stage of chronic asthma after an allergen challenge, thus regulating lung cDC1-
mediated eosinophil recruitment differently (59).  
Several lipids, such as prostaglandins and leukotrienes, are key mediators of the 
inflammatory response by acting as chemoattractant(s) of eosinophils. For example, 
leukotriene E4 and prostaglandin D2 (PGD2) induce eosinophil migration to the airways 
(16). PGD2 acts by binding to CRTH2 receptor (DP2) in eosinophils which induces its 
recruitment and activation (16). 
Nitric oxide (NO) synthesized from epithelial cells and vascular endothelial cells by 
inducible nitric oxide synthase enzyme is also responsible for the recruitment of eosinophils 
in addition to its function as a mediator of inflammation, and this correlates with the level of 
exhaled NO, which is a biomarker of asthma (16).  
Following the recruitment phase comes the effector phase. Autocrine secretion of IL-
5 by activated eosinophils enables them to survive within tissues in their own capacity as the 
secreted IL-5 inhibits apoptosis (16,60). Moreover, the adherence of eosinophils to 
fibronectin stimulates the secretion of other pro-survival mediators, such as GM-CSF and IL-
3, by activated eosinophils and hence, promotes their own survival (16,60). The additional 
effects of these cytokines enable eosinophils to persist in the airways for long periods and 











Eosinophils in inflamed tissues are also activated by antigen-specific IgGs and IgAs, 
but not IgE, as reported by a study conducted on the effects of antigens and antigen-specific 
immunoglobulins on eosinophil function (61).  
 
2.1.3 Airway hyperresponsiveness (AHR) and Mucus Hypersecretion  
 AHR occurs when there is a dysregulation of airway homeostasis. Allergen exposure 
causes events such as airway epithelium damage, mucus hypersecretion and ASM 
proliferation which leads to homeostasis imbalance (62). Eosinophils are highly involved in 
the development of these events through the release of its granule cytotoxic proteins via 
cytolysis, such as MBP, EPO, ECP, and EDN (51,53). The release of these granule proteins 
was shown to be triggered through chemokines, including eotaxin-1 and interferon-gamma 
(IFN- ) (53). MBP presents as two type of homologs, which are MBP-1 and MBP-2, with 
MBP-1 having a significantly alkaline pH and exerting direct cytotoxic effects on the host 
cells (51). MBP-1 also has a greater potency in histamine induction and leukotriene C4 
release from basophils as compared to MBP-2 (16). MBP and EPO were reported to cause 
AHR, although ECP and EDN did not (46). It was also reported that MBP induces bronchial 
hyperactivity by stimulating the release of histamine from mast cells and basophils (46,51). 
MBP can also cause bronchoconstriction by blocking acetylcholine receptor, M2, which is a 
negative feedback regulator for acetylcholine (53). Moreover, the combination of EPO, 
halides and hydrogen peroxide was shown to stimulate the release of mast cell mediators 
(51). 
In addition to cytotoxic cationic proteins, eosinophils secrete several cytokines which 
can contribute to the hallmarks of asthma. For example, IL-13 is a cytokine released by 
eosinophils which can enhance the differentiation of goblet cells to promote mucus 
hypersecretion, as well as cause AHR. Moreover, Th2 cells and ILC2 also produces IL-13  
(46).  
Additionally, eosinophils also produce lipid mediators in eosinophil lipid bodies, such 
as leukotrienes, which can also cause AHR and mucus hypersecretion (46). Eosinophilic 
leukotrienes stimulate bronchoconstriction and activation of basophils and mast cells, which 
further sustains the ongoing inflammation via the secretion of histamine, prostaglandins, and 
additional leukotrienes (53).   
The role of eosinophils in airway remodeling is further reinforced when mouse 
studies showed that mice with congenital eosinophil deficiency did not experience collagen 












2.1.4 Tissue damage and Airway remodeling 
Eosinophils cause persistent inflammation in the airways which causes continuous 
damage to the airway walls (53). During the reconstruction of the damaged airway, airway 
remodeling occurs as the basement membrane thickens and fibrosis occurs due to airway 
smooth muscle proliferation, goblet cell hyperplasia, extracellular matrix (ECM) proteins 
deposition, and new blood vessels formation (angiogenesis) (16,46,53). Airway remodeling is 
commonly associated with severe asthma phenotypes (63).  
Tissue damage occurs as a result of the cytotoxic effects of the eosinophilic granule 
proteins. The granule proteins exhibit varying strengths of toxicity when tested in vitro. 
MBP, EPO and ECP exert toxicity to several tissues, including bronchial epithelium, skin, 
heart and brain, whereas EDN only exhibits marginal toxicity (51). MBP, EPO and ECP were 
found to cause damage to epithelial cells in vitro when equivalent concentrations as found in 
asthmatic patients were administered (16,53). ECP is able to bind to and alter the 
permeability of cell membranes in the airway (46). 
The process of airway remodeling is also contributed by TNF- , as well as IL-1-  
according to recent studies, which activates eosinophils and stimulates the secretion of matrix 
metalloproteinase-9 (16,53). TNF-   and IL-1-   are also associated with persistent 
eosinophils recruitment (53). TGF-  is a growth factor secreted by eosinophils which can 
promote airway remodeling. Bronchial biopsies from asthmatic patients have shown that 
eosinophils are the primary source TGF-  (46). Studies have shown that TGF-  mRNA 
expression was upregulated in severe asthmatics and has correlation with the thickness of the 
basement membrane (16). TGF-  fucntions as a chemoattractant for fibroblast and stimulates 
fibroblast proliferation and differentiation into myofibroblasts and smooth muscle cells 
(46,53). Additionally, TGF-  upregulates the synthesis of collagen and glycosaminoglycans 
leading to ECM production and resulting in  tissue remodeling of the airways (46,53).  
Besides granule proteins and cytokines, eosinophils also secrete reactive oxidant 
species (ROS), such as hydrogen peroxide, superoxide anion and hydroxyl radicals, which 
contributes to airway inflammation and airway remodeling by damaging the cells and tissues 
of the airways and inducing the fibroblast hyperplasia (16,51,53). EPO stimulates the 












Zagai et al., stated that conditioned media (CM) collected from cultured human 
peripheral eosinophils and eosinophil cationic protein (ECP) extracted from human 
peripheral eosinophils significantly stimulated the migration of human lung fibroblasts in 
vitro in a concentration- and time-dependent manner (64). Thus, it was suggested that 
eosinophils affect the fibrotic response in asthmatics. As airway remodeling is associated 
with fibroblast recruitment, it was proposed that the stimulation of fibroblast migration by 
ECP may be an important mechanism in the remodeling process of extracellular matrix 
leading to airway fibrosis in asthmatics.  
 
2.1.5 ASM proliferation 
The co-culture of eosinophils isolated from asthma patients and ASM cells 
demonstrated an enhancement of ASM proliferation, which is inhibited by the presence of 
leukotriene antagonist, montelukast (46). A mutual relationship exists between eosinophils 
and ASM cells as ASM cells are able to produce eosinophilic cytokines (46). 
Based on the study done by Halwani et al., cysteinyl leukotrienes (CysLTs) released 
from eosinophils when they are in direct contact with airway smooth muscle (ASM) cells 
enhanced ASM proliferation (65). The requirement of direct cell contact between eosinophils 
and ASM cells to trigger CysLTs release were further confirmed when the administration of 
anti-adhesion molecule antibodies resulted in the inhibition of ASM proliferation (66). 
Additionally, it was proven that the increase in ASM proliferation was dependent on CysLTs 
released from eosinophils instead of ECM proteins as ASM proliferation was inhibited when 
leukotriene receptor antagonist (Montelukast) was co-cultured with eosinophils and ASM 
cells. The researchers concluded that airway remodeling in asthmatic patients can be 
attributed to eosinophil derived CysLTs which function to increase ASM mass through the 
enhancement of ASM proliferation.  
 
2.1.6 Eosinophilic pro-inflammatory cytokines and chemokines  
 Besides the direct cytotoxic effects of eosinophilic granule proteins on tissues, 
eosinophils produce and secrete a variety of pro-inflammatory mediators which contributes to 
the pathophysiology of asthma. For example, eosinophils produce a variety of Th2 cytokines 
in the airways of asthmatics, including IL-4, IL-5, and IL-13 (51). The recruitment of 
leukocytes to the airways is also regulated via the secretion of eosinophilic chemokines, such 
as CCL3, RANTES (CCL5), and eotaxin (CCL11) (51). Alternatively, neutrophil recruitment 











allergen challenge (51). Eosinophil activation is also mediated via Th1 cytokines released by 
eosinophils themselves, which is IFN-  (51). Thus, it is evident that eosinophils exhibit 
pleiotropic effects, which includes destruction of host tissues, regulation and potentiation of 
inflammatory pathways, as well as host defense. The severity of asthma symptoms in patients 
is worsened by these eosinophilic functions. Therefore, therapies which target eosinophils 




2.2 Eosinophils as Biomarkers of Asthma 
Heterogeneity exists in asthma with regards to its underlying pathophysiology, 
clinical signs and symptoms, and treatment response. The use of merely clinical and 
physiological assessment has become inadequate in the accurate prediction of the underlying 
mechanism of the disease or the treatment response. Thus, additional testing for biomarkers 
in conjunction with examination of clinical signs and symptoms of the patient will be able to 
help identify asthma phenotypes and endotypes, anticipate the disease progression and its 
prognosis, as well as enhance the precision therapy for asthma (67). Eosinophil counts have 
become a useful biomarker in the assessment of asthma.  
Szefler et al., reported that the measurement of total eosinophil counts and sputum 
eosinophils as biomarkers for asthma are recommended as supplemental outcome measures 
(68). Supplemental outcome measures are defined as outcomes of asthma for which 
standardized definitions and specific methods of measurement exists, and their validity has 
been proven but they remain as an optional inclusion in funded clinical asthma research (68). 
The eosinophil measurements are obtained through complete blood counts. In addition to 
sputum eosinophils, nasal discharge eosinophils with asthma symptoms may also be a 
predictive factor for persistent asthma (69). As such, testing for nasal discharge eosinophils 
with asthma symptoms increases with age (69). 
 The severity of sputum eosinophilia in asthma can be assessed using various 
biomarkers. However, the biomarkers’ diagnostic accuracy might vary between different 
asthma phenotypes. Westerhof et al., carried out an investigation to determine the accuracy 
of several biomarkers for the detection of sputum eosinophilia in different phenotypes of 
adult asthma, such as total IgE, area under curve (AUC), and exhaled nitric oxide fraction 
(FeNO) (70). Among the different asthma phenotypes of adult patients used for comparison 











and non-smoking asthma patients. The findings showed similarities in AUCs for blood 
eosinophils and FeNO among the various asthma phenotypes whereas total IgE showed 
higher accuracy in the detection of sputum eosinophilia in non-obese and non-atopic 
asthmatics as compared to obese and atopic asthmatics (70). The researchers concluded that 
the measurement of blood eosinophils and FeNO as sputum eosinophilia biomarkers, 
irrespective of asthma phenotype, showed superior diagnostic accuracy as compared to total 
IgE (70). A separate study also showed that blood eosinophils can most accurately identify 
sputum eosinophilia in patients with varying severities of asthma, such as mild, moderate or 
severe asthma (71). Thus, eosinophils found in blood circulation can be used to facilitate 
individualized asthma treatments.   
 Nevertheless, some studies have shown that despite statistically significant 
associations, blood eosinophil and neutrophil counts, FeNO and IgE levels, FEV1 percentage 
and age are poor surrogate biomarkers, both singularly and in a combination, for predicting 
sputum eosinophil and neutrophil percentages (72).  
 Phenotyping based on airway inflammation severity is often applied to asthmatic 
patients. According to a study done by Walsh et al., the relationship between rates of 
exacerbations and the phenotype of severe asthma was investigated based on longitudinal 
measures of sputum eosinophils and neutrophils (73). The results demonstrated that asthmatic 
patients with persistent eosinophilic phenotype experienced shorter intervals before the first 
exacerbation and an increased risk of exacerbation over a 1-year period as compared to those 
with non-eosinophilic phenotype. However, no observable changes were noted in time to first 
exacerbation or exacerbation risk among neutrophilic phenotypes.  
 A cohort study carried out in UK also reported that asthmatic patients with blood 
eosinophil numbers >400 cells/μL experienced a worsening in asthma control and more 
severe exacerbations, as defined by the increased use of asthma relievers, asthma-related 
hospitalization, oral corticosteroids use, or antibiotics prescriptions (74).  
Petsky et al., reported, in a systemic review, that carrying out therapy adjustment 
according to airway eosinophilic markers, such as sputum eosinophil counts and exhaled 
nitric oxide, significantly decreased the risk of asthma exacerbations (75). However, no 
significant impact was observed with regards to dose of daily inhaled corticosteroid, asthma 
control or lung function.  
 Periostin is a proposed novel biomarker of eosinophilic airway inflammation. A 
specific asthma subset as characterized by the expression of Th2 cytokine-inducible genes in 











which is present in about 50% of asthma patients and is associated with eosinophil-mediated 
airway inflammation. In a study done by Jia et al., an assay for peripheral blood periostin 
protein was developed to investigate its potential as a biomarker in order to designate 
selective therapies for specific groups of asthma patients (76). The patients used for sample 
collection were asthmatics with persistent symptoms in spite of inhaled corticosteroid 
administration at maximum doses. The results showed that asthma patients with evident 
eosinophilic airway inflammation demonstrated a significant increase in levels of serum 
periostin as compared to those with minimal eosinophilic airway inflammation (76). Serum 
periostin levels also proved to be a more useful predictor of eosinophilia in airways than 
other indices, such as peripheral blood eosinophil, IgE and FeNO levels (76). The researchers 
concluded that the occurrence of eosinophilic airway inflammation can be predicted using 
periostin as a systemic biomarker in asthma patients and thus, this can potentially be a utility 
for selecting patients for emerging asthmatic therapeutics, such as ICS and biologics, 
targeting Th2 inflammation (76). Simpson et al., also reported that serum and sputum 
periostin levels have high correlation with sputum eosinophil counts (77). Periostin 
concentrations were also found to be higher in serum than in sputum. However, the ability of 
periostin levels to predict the presence of eosinophilic asthma was modest.  
 Besides periostin, eosinophil peroxidase (EPO) level are also reported in several 
studies to have correlation with sputum eosinophil levels. Rank et al., carried out a study to 
compare nasal, pharyngeal, and sputum EPO levels with induced sputum eosinophil 
percentage and found that there was a strong association between nasal and pharyngeal EPO 
levels and the percentage of eosinophils of induced sputum. Another study carried out by 
Nair et al., concluded that EPO levels assayed by ELISA was an appropriate surrogate 
marker of eosinophils and/or eosinophil degranulation in sputum of respiratory patients (78). 
  ILC2s are recognized as another novel biomarker for eosinophilic airway 
inflammation. In an investigation carried out by Liu et al., the inherent diagnostic ability of 
ILC2 was compared to standard biomarkers of eosinophilic asthma, including age, sex, BMI, 
number of blood eosinophils, IgE, and FeNO (79). The results concluded that ILC2 levels 
were significantly elevated in patients with eosinophilic asthma and the ILC2 percentage was 
the most significant component of eosinophilic airway inflammation as compared to the other 
biomarkers (79). Moreover, ILC2 percentage showed high sensitivity and specificity in 
differentiating patients with eosinophilic asthma from asthma patients without eosinophilic 
inflammation (79). Thus, ILC2 is a prospective substitute biomarker for eosinophilic airway 











patients for beneficial asthmatic therapies targeting Th2 inflammation. There is a six-gene 
signature paper that predicts exacerbations in the severe asthma patients, this six-gene sig has 
been proposed as a marker for severe asthma exacerbations, and more recently in COPD 
(80,81).  
 Biomarkers of eosinophilic inflammation appears to differ between severe asthmatic 
patients with concomitant obesity and normal asthmatic patients. In a study done by Desai et 
al., obese severe asthmatic patients demonstrated significant elevations in submucosal 
eosinophils and sputum IL-5, however no changes were observed in sputum eosinophils (82). 
Hence, supplementary investigations should be performed to determine if eosinophil-targeted 
therapies or diet and lifestyle modifications are more effective in providing anti-inflammatory 
effects in obese patients with asthma.  
 
 
2.3. Bacteria and eosinophils  
 A greater diversity of microorganisms with altered compositions are known to be 
present in asthmatic patients, for example, more Proteobacteria and less Bacteroidetes as 
compared to healthy subjects (83). Hence, it was proposed that the composition of airway 
microbiome has correlations with the type of airway inflammation (84,85). A study carried 
out by Sverrild et al., revealed that the level of eosinophilic airway inflammation has 
correlations with the varying airway microbiome constituents in asthma patients (83). A more 
abundant bacterial profile was obtained from patients with the lowest eosinophil counts, for 
example, a greater proportion of Neisseria, Bacteroides, and Rothia species and a lower 
proportion of Sphingomonas, Halomonas and Aeribaccilus species as compared to asthma 
patients with greater eosinophil counts and healthy subjects (83). The type of bacterial 
species also affects eosinophil functionality differently. A study conducted by Hosoki et al., 
showed that Staphylococcus aureus (SA) stimulated the release of EDN in a dose-dependent 
manner, but Haemophilus influenzae (HI) and Prevotella sp. (PS) did not (86). SA, HI and PS 
all significantly enhanced superoxide generation, but SA had a greater effect which 
significantly induced a greater eosinophilic TNF-α production as compared to either HI or PS 
(86). Conversely, HI and PS induced IL-10 production more strongly than SA (86). Thus, it 
was concluded that SA may be associated with exacerbation of eosinophilic inflammation in 
asthma whereas HI and PS may be involved in its inhibition.  
 











 Asthma is conventionally treated with beta-agonists, anti-cholinergics and inhaled 
corticosteroids (ICS). In addition, biologics are commonly used as an alternative to treat 
severe and refractory asthma in which conventional treatments show limited efficacy or 
intolerable side effects. Monoclonal antibodies, such as those targeting IL-5, IL-5R , IgE and 
IL-4R , have shown favourable outcomes in clinical trials for the treatment of severe, 
uncontrolled asthma (87). Patients with severe eosinophilic asthma were also successfully 
managed with biologics which target IL-5, IL-4, IL-13, and IgE. This is because local 
eosinophilopoiesis is hypothesized to be the predominant mechanism that results in on-going 
airway eosinophilia and steroid requirements in patients with severe asthma, and these agents 
either directly or indirectly targets eosinophils which leads to improved asthma outcomes, 
such as reduced exacerbations and steroid-sparing effects. Among these biologic therapies, 
anti-IL-5 drugs, including reslizumab, mepolizumab, and benralizumab are most used and 
supported as adjuncts for severe eosinophilic asthma therapy and poor asthma control. 
Studies have shown that treatments that target IL-5/IL-5R  in severe eosinophilic asthma 
patients resulted in significant decrease of blood and sputum eosinophilia, reduction of 
exacerbation episodes, along with major improvement in clinical symptoms (15). Patients on 
anti-IL-5 therapies experienced approximately half of the asthma exacerbation rates (88). 
However, improvements in health-related quality of life (HRQoL) scores and lung function 
could not be confirmed due to insufficient evidence (88). With regards to safety, patients 
taking reslizumab, mepolizumab or benralizuamb did not experience any serious adverse 
effects (88). Moreover, novel therapies targeting other eosinophil-associated factors and their 
receptors have also been studied, including those that target CC-chemokine receptor 3 
(CCR3), prostaglandin D2 (PGD2), thymic stromal lymphopoietin (TSLP), as well as novel 
oligonucleotide therapies.  
 
2.4.1 Reslizumab 
 Reslizumab is a humanized, neutralizing anti-IL-5 monoclonal antibody which acts by 
binding to IL-5 to block its interaction with its receptor (89,90). IL-5 receptors (IL-5R) can 
be found on the surfaces of eosinophils. IL-5 functions to increase the activation and 
maintenance of eosinophils, which drives eosinophilic inflammation (89). As such, the 
blocking of IL-5 binding with its receptor on eosinophils leads to the disruption of eosinophil 
maturation and promotes apoptosis (91). Many studies have shown the beneficial outcomes 











experiment comparing reslizumab and placebo use in asthma patients, the reslizumab group 
experienced  significantly less asthma exacerbations as compared to the placebo group (91). 
The results of the study concluded that reslizumab can be effectively used for treating asthma 
patients with persistent eosinophilia who are inadequately controlled with corticosteroids 
(91). Another study reported that patients that were administered 3.0 mg/kg of IV reslizumab 
every month experienced better asthma control as well as an improved lung function (90). 
The study also highlighted that patients with an increased eosinophil load that is inadequately 
managed with moderate-high doses of ICS benefited the most from reslizumab therapy (90). 
When compared to benralizumab, which targets IL-5R , it was shown that reslizumab 
confers higher efficacy than benralizumab in patients with eosinophilic asthma (89).  
 
2.4.2 Mepolizumab  
 Another anti-IL-5 monoclonal antibody with the same mechanism of action as 
reslizumab is mepolizumab, which has shown to be useful for treating eosinophilic asthma in 
several studies. In a research carried out by Haldar et al., the efficacy of mepolizumab in the 
treatment of patients with refractory eosinophilic asthma and history of recurrent 
exacerbations was investigated. who were administered mepolizumab therapy for 1 year 
experienced reductions in exacerbation rates as well as improvements in the Asthma Quality 
of Life Questionnaire (AQLQ) scores (92). At the end of the study, the patients who 
undergone 1 year of therapy reported less exacerbations, scored higher in the Asthma Quality 
of Life Questionnaire (AQLQ), and showed significant reductions in levels of blood and 
sputum eosinophils (92). However, mepolizumab showed no significant distinction in 
symptoms, post- bronchodilator FEV1, or airway hyperresponsiveness when compared to 
placebo and other anti-IL-5 therapies (92). Another study demonstrated the effects of 
mepolizumab in prednisone-sparing. Nair et al., reported that mepolizumab administered to 
asthma patients with high sputum eosinophils despite continuous prednisone therapy 
effectively lowered blood and sputum eosinophil counts and thus, proved the prednisone-
sparing effect of mepolizumab (93). Furthermore, Sehmi et al., demonstrated that 
subcutaneous mepolizumab therapy significantly attenuated systemic differentiation of 
eosinophils in severe eosinophilic asthma patients, as observed from the decrease in blood 
eosinophils and elevated eosinophil-lineage-committed progenitors (EoP) counts in the 
mepolizumab group (94). However, mepolizumab had no significant effects on mature 
eosinophils, sputum EoP counts or maintenance dose of prednisone, indicating that 











Thus, it is evident that airway eosinophilia and severe eosinophilic asthma can be optimally 
controlled by targeting IL-5 pathway-associated local airway eosinophil differentiation. In a 
comparison study on the effectiveness of anti-IL-5 therapies, mepolizumab showed 
superiority in reducing the frequency of asthma exacerbations and improving asthma control 
over reslizumab or benralizumab in severe eosinophilic asthma patients with identical 
baseline levels of blood eosinophils (95).  
Despite these studies that showed a positive outcome from mepolizumab therapy, 
there exists some concerns regarding the potential risk of ‘rebound’ eosinophilia following 
treatment cessation (55). Another study has also showed that mepolizumab treatment 
cessation resulted in rapid blood eosinophilia and subsequent worsening of asthma symptoms 
and exacerbations (55). Thus, further studies should be carried out to ensure the safety of 
eosinophil-targeted therapies. Nonetheless, mepolizumab is approved by both FDA and EMA 
to be used in patients >6 years of age with severe eosinophilic asthma. The primary benefits 
of mepolizumab include improvements in the lung function (forced expiratory volume) and 
marked reductions in asthma exacerbations (96).   
 
2.4.3 Benralizumab 
 Benralizumab is a humanized, afucosylated, IgG1κ monoclonal antibody which 
prevents the receptor interaction of IL-5 by binding to IL-5R  via its Fab domain. As a 
result, eosinophilia is reduced in blood, tissue and bone marrow due to the inhibition of 
eosinophil differentiation and maturation. In addition, benralizumab also depletes eosinophils 
in tissues and systemic circulation via antibody-dependent, cell-mediated cytotoxicity as it 
can bind to the RIIIa region of the Fc  receptor on NK cells, neutrophils and macrophages 
through its afucosylated Fc domain (97,98). The dual-function of benralizumab allows for a 
more rapid and sustained reduction of eosinophilia than other IL-5-targeted monoclonal 
antibodies (97). Benralizumab therapy has shown positive outcomes in both moderate-severe 
asthma patients as well as eosinophilic chronic obstructive pulmonary disorder (COPD) 
patients (99). Sridhar et al. conducted a research in which eosinophilic asthma and 
eosinophilic COPD patients were given benralizumab subcutaneously and the results 
demonstrated that benralizumab could selectively modulate eosinophil- and basophil-
associated blood proteins and genes (99) Following benralizumab administration, eosinophil 
chemokines (eotaxin 1 and 2) were upregulated significantly in both the asthmatic and COPD 
patients (99). Furthermore, the expression of eosinophil- and basophil-associated genes were 











selectively modulate blood proteins and eosinophil- or basophil-associated genes, with 
alterations occurring prominently in eosinophil-high patients rather than eosinophil-low 
patients (99). Randomized clinical trials have also provided evidence on the optimal safety 
profile of benralizumab, as well as its efficacy in reducing asthma exacerbations, steroid-
sparing and improvement of lung function (98). When compared to reslizumab, benralizumab 
was associated with a significantly improved lung function in asthma patients with severe 
eosinophilia (≥400 cells/μL) (95). Benralizumab is approved by FDA as an add-on 
maintenance therapy for use in patients with severe eosinophilic asthma aged over 12 years. 
The primary benefits include significant reductions in the asthma exacerbations, 
improvements in lung function parameters (forced expiratory volume in one second) and 
marked reduction in prescription of inhaled corticosteroids (100).  
 
2.4.4 Omalizumab 
 Bronchial asthma is not only associated with elevations in pro-inflammatory Th2 
cytokines, but also high levels of IgE. Besides the roles of Th2 cytokines in eosinophil 
differentiation, maturation, migration, and survival, they also contribute to the production of 
IgE. Omalizumab is an anti-IgE monoclonal antibody that can effectively reduce peripheral 
blood eosinophil (PBE) counts as well as airway eosinophil counts in asthmatic patients 
(101). Massanari et al., reported that omalizumab had an inhibitory effect on eosinophils as 
observed from the lowered PBE counts in moderate-severe persistent allergic asthma patients 
who were on moderate-high doses of ICS (102). It was observed that patients who were 
administered omalizumab therapy demonstrated a significant decrease in PBE counts from 
baseline, with patients that have post-treatment free IgE levels < 50 ng/mL showing a larger 
decrease (102). In both steroid-reduction and steroid-stable phases of the studies, larger 
decreases in PBE counts were observed as compared to placebo (102). Thus, omalizumab 
treatment groups consistently experienced a pattern of lowered PBE counts and favourable 
clinical outcomes. Omalizumab is approved by both FDA and EMA to be used in patients 
over 12 years with moderate allergic asthma demonstrating raised levels of IgE. Omalizumab 
reduces the asthma exacerbation rates and, in some cases, reduces the corticosteroid 
prescriptions (103). 
  
2.4.5 Dupilumab  
 Dupilumab is a novel anti-cytokine biologic drug used in the treatment of asthma. 











cytokines that can stimulate eosinophil recruitment and migration to local airways. IL-4 and 
IL-13 contributes to the pathophysiology of the typical characteristics of asthma, such as 
chronic airway inflammation, tissue remodeling and airway hyperresponsiveness (104). 
Dupilumab is a monoclonal antibody that can inhibit the interaction between IL-4 and IL-13 
with IL-4Rα. In a recent study, dupilumab significantly attenuated Th2 cell-associated 
inflammatory biomarkers, which is correlated with an improvement in lung function and 
airway symptoms as well as reduction of asthma exacerbations in patients with difficult-to-
control asthma (104). Dupilumab is approved to be used as an add-on therapy in patients over 
12 years of age and who demonstrate a poorly controlled moderate-to-severe asthma 
phenotype. Dupilumab has been shown to prevent asthma exacerbations and improvements in 
lung function (105).  
 
2.4.6 MEDI-563 
 In addition to the commonly used anti-IL-5 drugs, MEDI-563 is a novel humanized 
anti-IL-5R   monoclonal antibody that has been developed with an enhanced effector 
function in the management of asthma (106). Kolbeck et al., reported that MEDI-563 caused 
both eosinophils and basophils to undergo antibody-dependent cellular cytotoxicity (ADCC) 
in vitro (107). MEDI-563 administered to non-human primates also decreased peripheral 
blood and bone marrow eosinophil counts (107). Thus, this study suggests that the focus of 
anti-asthma biologic therapies should be shifted from the passive removal of IL-5 to the 
reduction of eosinophil and basophil counts via ADCC mechanism.  
 
2.4.7 Novel CCR3 receptor antagonist  
Agents which target eosinophil cell surface-structures, for example CC-chemokine 
receptor 3 (CCR3), have also showed efficacies in decreasing blood and tissue eosinophil 
levels (108). Ki19003 (4-[[5-(2,4-dichlorobenzylureido) pentyl][1- (chlorophenyl) ethyl] 
amino] butanoic acid) is a novel CCR3 antagonist. CC-chemokine ligands (CCL), such as 
CCL11, CCL24 and CCL26, are associated with eosinophil chemotaxis (109). A study done 
by Komai et al., administered Ki19003 to ovalbumin-induced BALB/c mice to study its 
effects on airway remodeling in a mouse model of allergic asthma (109). It was observed that 
Ki19003 inhibited antigen-induced elevations in the number of eosinophils found in 
bronchoalveolar lavage fluid (BALF), but other cells were not affected (109). Furthermore, a 
dose-dependent increase in TGF- 1 production in BALF and hydroxyproline amount in 











resulted in the attenuation of allergen-induced subepithelial and peribronchial fibrosis (109). 
Hence, it can be concluded that CCR3 antagonism can prevent eosinophil airway infiltration 
as well as the progression of subepithelial and peribronchial fibrosis following an allergen 
challenge. Therefore, the process of airway remodeling, which is a prominent feature of 
allergic asthma, can potentially be prevented using CCR3-targeted treatments.  
 
2.4.8 PGD2 antagonist  
 Chemoattractant receptor-homologous molecules expressed on T-helper type 2 cells 
(CRTH2) that mediates chemotactic response to PGD2 are also expressed on eosinophils 
(110). PGD2 inhibitors, such as timapiprant and fevipiprant, have been studied for their 
effects on eosinophilia. Timapiprant was shown to improve conditions of mild-moderate 
eosinophil-mediated allergic asthma patients whereas the administration of fevipiprant 
therapy to patients with moderate-severe asthma who were not adequately managed with ICS 
resulted in reduced sputum eosinophil counts and subsequently, attenuation of eosinophilic 
airway inflammation (111). However, the phase III trial of fevipiprant did not show marked 
clinical improvements in patients with poorly controlled asthma (112).  
 
2.4.9 Anti-TSLP 
 TSLP plays a part in eosinophilic inflammation by recruiting eosinophils following 
epithelial damage. AMG 157 is a human anti-TSLP monoclonal IgG2λ which inhibits the 
interaction and binding of TSLP to its receptor. A Phase I clinical trial conducted by 
Gauvreau et al., reported that AMG 157 treatment administered to allergic asthma patients of 
mild severity significantly reduced FeNO in addition to blood and sputum eosinophil levels 
following and prior to allergen (113). Moreover, the AMG 157 treatment group experienced a 
greater reduction in maximum percentage decrease in FEV1 during late response than the 
placebo group, with a greater reduction occurring as the treatment progressed (113). Thus, 
the researchers concluded that AMG 157 attenuates bronchoconstriction and other indications 
of respiratory inflammation pre- and post-allergen challenge.  
 
2.4.10 Novel oligonucleotide therapy 
 Oligonucleotides, such as siRNA and miRNA, are promising novel therapeutic 
strategies for the treatment of various respiratory disorders via their gene silencing or RNA 
interference abilities (114–117). An oligonucleotide-based therapy, TPI ASM8, was studied 











mild allergic asthma. TPI ASM8 consists of two phosphorothioate antisense oligonucleotides 
(AON) which are modified, with one targeting CCR3 receptor and another targeting the beta 
chain (βc) which is common among IL-3, IL-5 and GM-CSF receptors. According to a study 
carried out by Imaoka et al., patients with mild allergic asthma who were administered 
nebulized TPI ASM8 following an allergen challenge showed reductions in sputum 
eosinophils, early and late asthmatic responses, as well as airway eosinophil progenitor cells 
(118). Thus, it was concluded that the accumulation of eosinophils and their progenitor cells 
in airways of asthmatics can be inhibited successfully via TPI ASM8-mediated CCR3 and βc 
expression blockade. Therefore, further efforts of developing novel therapies that inhibit 
accumulation of airway progenitor cells should be taken.  
 
2.4.11 Corticosteroids  
 Oral corticosteroids (OCS) are one of the mainstay therapies for the long-term 
management of severe asthma, which is characterized by persistent asthma symptoms and 
airway inflammation despite maximum efforts using anti-asthma treatments. Corticosteroids 
effectively acts on various components of the Th2 inflammatory pathway and its use can 
result in rapid attenuation of eosinophils-associated inflammation as well as long-term 
reduction in airway hyperresponsiveness (119). As such, corticosteroids confer better 
responses in asthma patients with eosinophilic inflammation as compared to neutrophilic 
inflammation (120). However, a major drawback to corticosteroid use is the development of 
corticosteroid resistance or insensitivity, which frequently occurs in long-term use of 
corticosteroids. This feature is especially prominent in severe asthmatics with persistent Th2 
inflammation despite regular OCS use. Thus, biological therapies are introduced as 
alternative therapies although a large proportion of asthmatic patients will still require the use 
of OCS to control their asthma (119). The therapeutic action of OCS on inflammatory 
cytokines and eosinophils are proven in several studies. In a study conducted by Dente et al., 
short-term courses of OCS reduced both sputum eosinophilia and sputum pro-inflammatory 
cytokine concentrations, in addition to improving lung function in patients with severe 
refractory asthma (121). The improvement of pulmonary function was concluded from the 
significant increase in FEV1 following OCS treatment/ The prednisone group also exhibited a 
significant decrease in sputum eosinophil percentages and concentrations of IL-5 and IL-8 
(121). It was also noted that prednisone treatment only showed positive effects in patients 
with baseline sputum eosinophilia, whereas only a significant decrease of sputum IL-8 was 











relationship between CS dose and PBE counts displayed in severe eosinophilic asthma 
patients. Prazma et al., predicted a model in which reducing the daily dose of OCS by 5 
mg/day resulted in a 41% increase in PBE counts (122). Another study reported that ICS dose 
increment from medium to high dose in patients with uncontrolled asthma resulted in a 
significant reduction of blood eosinophil concentrations (123).  
 
2.5 Alternative therapies affecting eosinophils in the treatment of asthma 
 
2.5.1 Quercetin 
Known to be present as flavonoids in fruits and vegetables, quercetin was shown to be 
an anti-inflammatory agent with the potential use in the treatment of asthma (124). In this 
case, the clinical features of asthma were relieved by suppressing the activation of the 
signaling pathway of NF-κB which results in the reduced production of proinflammatory 
mediators associated with airway hyperresponsiveness and airway inflammation (124). Two 
other studies have also insinuated quercetin’s role in the prevention of eosinophilic airway 
inflammation via the attenuation of eosinophil activation, particularly the production of 
chemokines (125,126). In the study by Cherk Yong et al., quercetin was encapsulated into a 
lipid crystalline nanoparticle (LCN) to overcome its limitation in terms of bioavailability as 
well as aqueous solubility which resulted in the successful exhibition of an improved anti-
inflammatory effect of quercetin when formulated as such (124). 
 
2.5.2 Curcumin 
Curcumin is a constituent originating from the spice, turmeric, that is thought to be a 
potential remedy for the management of asthma (127,128). Similarly, to quercetin, curcumin 
possesses anti-inflammatory properties which relieve airway inflammation of allergic nature 
as well as airway hyperresponsiveness through the suppression of the activation of the 
signaling pathway associated with NF-κB and the attenuation of eosinophil production (128). 
Its clinical application is also limited by the same reasons seen in quercetin (128,129). Hence, 
Ng et al., sought to load curcumin into liposomes as liposomes were noted to be able to 
modify a system’s pharmacokinetic and biodistribution profiles (128–130). The study 
managed to overcome the limitation of curcumin’s unfavourable solubility as well as 
demonstrate the sustained release properties attained through the encapsulation of curcumin 
in a liposome, indicating that curcumin loaded liposomes could be an appealing option for the 












3.0 Eosinophils and COPD  
 
Chronic obstructive pulmonary disease is described by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) as a disease that can be commonly prevented and 
treated (131–134). However, COPD is noted to be among the most substantial causes of 
morbidity and mortality globally and this has caused a significant burden which is ever 
growing on the economy and society (131). This disease is characterized by the poorly 
reversible limitation of airflow which is commonly progressive and the elevated response to 
chronic inflammation that occurs in the peripheral airways and lung parenchyma due to the 
inhalation of noxious particles or gasses which is primarily (but not exclusively) caused by 
smoking tobacco (131,135–137). Emphysema and small airway fibrosis may result from the 
chronic inflammation because of the destruction of parenchymal tissue and disruption of 
mechanisms of repair and defense which causes the arise of the characteristic symptoms 
associated with COPD (131,135). As the disease progresses, so does the degree of 
inflammation which results in the elevation of neutrophil, macrophage and lymphocyte levels 
within the airway lumen (137). The increase in numbers of neutrophil and macrophages 
occur due to the activation of pattern recognition receptors which precipitates an innate 
immune response that also gives rise to the activation of airway epithelial cells as well as 
mucus secretion (137,138). An increase in T lymphocyte and B lymphocyte numbers in the 
lungs is seen when adaptive immunity is activated in the latter course of the disease which 
might result in the amplification of neutrophilic inflammation due to the increment in CD4+ 
T helper 17 cells present in the lungs (137). Although various inflammatory cells are 
implicated in COPD, neutrophils are by far the most abundant and has been extensively 
associated with the pathogenesis of COPD (139–143). However, it has been reported that 
some COPD patients without asthma have elevated numbers of eosinophils in their airways 
instead during exacerbations and clinical stability (Figure 3) (137,141,144,145). This is 
commonly seen in asthmatic patients where eosinophilic inflammation is known to be a 
distinguishing feature of the disease but the presence of a subdivision of COPD patients with 
eosinophilic airway inflammation has been reported (141,143,144,146–148). COPD patients 
with this phenotype are known to show the most significant response to corticosteroid 
treatment as well as an increased risk of exacerbation relapse and hospital readmissions 
(140,142,143,146,149,150).  











3.1 Role of eosinophils as biomarkers in COPD 
Blood eosinophils have been recognised by several studies to be potential a biomarker 
of disease severity and clinical outcome in exacerbations of COPD (151–153). The 
measurement of eosinophils present in the blood, as a proxy for eosinophils present in tissues, 
has become an essential biomarker for the prediction of risk of exacerbations in COPD 
patients (154). Elevated counts of blood eosinophil in COPD has been well associated to the 
clinical features of the disease. Patients with an increment in blood eosinophil levels of ≥ 450 
cells/μl during stable disease reportedly reflected a higher rate of exacerbation by 13% in the 
following year compared to patients with lower numbers (152). Another studied showed, 
amid COPD patients in the general population, increment of blood eosinophil counts > 
0.34 × 10
9
 cells/L were affiliated with a heightened risk of developing severe exacerbations 
by 1.76-fold (155).  However, blood eosinophils singularly were not a dependable biomarker 
to predict the severity of the disease, the associated risk of exacerbations, or sputum 
eosinophilia (156). Instead, elevated sputum eosinophil counts acts as a more reliable 
biomarker compared to elevated concentrations of blood eosinophils for the identification of 
a subdivision of patients with more disease severity and more persistent exacerbations (156).  
Eosinophil concentrations may also be a useful biomarker for the prediction of 
outcomes in COPD as increased number of blood eosinophil  in COPD were related with a 
longer survival period and a higher incidence of hospital readmissions (157–159). A study 
also suggested that the deterioration of pulmonary function tests could be predicted according 
to number of blood eosinophil (158). Low blood eosinophil counts on the other hand, is 
predictive of a poorer clinical outcome and longer durations of hospital admission (158–160). 
However, a few studies report that blood eosinophil counts do not appear to be related to 
mortality (158,161). It is also noted that blood eosinophil concentrations can be utilized as a 
biomarker for the prediction of readmissions of patients suffering from severe COPD 
exacerbations (162). Moreover, Bélanger et al., suggests a relationship between greater blood 
eosinophil count upon admission of a COPD exacerbation and increased rate of readmissions 
(161–163). 
 
3.2 Eosinophils as a guide for COPD treatment 
Although airway eosinophilic inflammation in COPD may worsen the stabilization of 
symptoms, it can be used as to predict the benefit of treatment involving inhaled and oral 
corticosteroid (157,163,164). A review by Hillas et al., states the benefit of corticosteroid use 











eosinophils counts (165). The review also covered a post hoc analysis of three randomized 
controlled trials (RCTs) which demonstrated that COPD patients with eosinophil counts > 
100 cells had a reduced risk of AECOPD of 25% when  a combination of budesonide and 
formoterol was used compared to formoterol alone (165,166). Two other studies also showed 
results of greater decrease of exacerbation frequency in patients as the blood eosinophil count 
increased when inhaled corticosteroids (ICS) was added to the therapy alongside a long-
acting β-agonist (LABA) whereas patients who were on a single therapy regimen of LABA 
exhibited progressively increasing rate of exacerbations as the eosinophil counts increased 
(165,167–169). In addition, Vestbo et al., has also demonstrated in his study that patients 
reflecting blood eosinophil counts  ≥ 2% experienced reduced exacerbations of 30% with the 
use of either a regimen consisting of single inhaler extra fine triple therapy or long-acting 
muscarinic antagonist (LAMA) (170). Likewise, the 2019 GOLD COPD Strategy document 
states that blood eosinophil levels are to be used to guide ICS therapy in the treatment of 
stable COPD patients and frequent exacerbators as well (171). 
It was also suggested that ICS withdrawal in COPD patients with eosinophil counts  ≥ 
4% and a history of exacerbations may increase the possibility of developing AECOPD 
(172,173). A trial reported that the continuous use of ICS reduced the exacerbations of 
moderate and severe grades in patients with either ≥ 4% relative eosinophil count or ≥ 300 
cells/mL absolute eosinophil count compared to patients who were tapered off  ICS (173). 
Similarly, the SUNSET trial identified that as ICS was tapered off, it led to a heightened risk 
of exacerbations among patients with an eosinophil count of ≥ 300 cells/mL (174). However, 
several studies including the Clinical Practice Research Datalink (CPRD) reported that ICS 
withdrawal among COPD patient did not affect the exacerbation risk of moderate-to-severe 
severity significantly (172,175–177). The difference in findings might be due to the use of 
different patient groups where the WISDOM trial had made use of patients with COPD of 
high severity, a past medical history of exacerbations and prior treatment with ICS before the 
trial, the SUNSET trial studied COPD patients treated with ICS regimens long-term and did 
not have persistent exacerbations whereas other studies such as CPRD utilised a patient 
population not at high exacerbation risk where the usage of bronchodilators and ICS are 
lesser than clinical trials (172–174). Nevertheless, both the WISDOM trial and CPRD 
reported a similar finding whereby patients with eosinophil counts more than 6.0% do not 
have an increased risk of exacerbations on withdrawal of ICS (172,173). 
The study by Oshagbemi et al., did not report findings of increased all-cause mortality 











from ICS regimen but there are several studies that have evidence which conflict this finding 
(172,178,179).  
Even though, blood eosinophil counts can be regarded as a guide to treating COPD, it is 
critical to remember that COPD patients, blood eosinophils are not influenced by ICS use 
(165,180). This is because there is pronounced variation in blood eosinophil levels (165,181–
183). Hence, one measurement of blood eosinophil counts may not be sufficient for the 
accurate choice of utilizing ICS in a COPD patient’s regimen (165).  
 
3.3 Therapeutic targets for eosinophilic inflammation in COPD 
COPD treatment regimens are largely associated with use of bronchodilators 
which treat the symptoms but not the underlying inflammation nor disease progression 
(135). Biologics targeting immune mediators such as IL-5 are showing promising results in 
COPD patients with the eosinophilic phenotype (135,184). IL-5, a key eosinophil cytokine 
mediates its differentiation, proliferation, survival, and activation via the IL-5 receptor (184–
187). Humanized monoclonal antibodies, mepolizumab and benralizumab reduces blood and 
tissue eosinophil counts via the inhibition of IL-5 binding to eosinophil surface receptors and 
binding to interleukin-5 receptor α respectively (185,186,188–190). These two drugs have 
been known to successfully reduce eosinophilic inflammation and lower exacerbations rates 
in asthma (135). However, mepolizumab was not able to obtain the approval from the  US 
Food and Drug Administration (FDA) to be used as an adjuvant to the maintenance regimen 
for COPD patients with eosinophilic inflammation because one of two phase III studies 
carried out showed no evidence of efficacy (135,184,186,187). Studies on benralizumab have 
been inconsistent in which it demonstrated a decrease in rate of exacerbations in a Phase IIa 
trial consisting of COPD patients with eosinophilic inflammation but failed to reach the 
primary end point in two phase III trials consisting of COPD patients with exacerbation 
histories of moderate to very severe grades (135,185,189,190).  
Another target of interest in eosinophilic COPD is the transcription factor, GATA3 
which plays a part in the activation of Th2 cells and action on the type 2 innate lymphoid 
cells (ILC2 cells) (191). These interactions result in increased cytokine IL-4, IL-5 and IL-13 
production which are thought to moderate airway eosinophilia in non-allergic asthma and 
COPD (191). SB010 is a drug that consists of the active constituent, DNAzyme hgd40 which 
specifically binds to and cleaves the mRNA of GATA3 and has been evaluated in human and 
animal models (191). Turowska et al., reports significantly reduced GATA3 mRNA along 











inflammation when treated with SB010 (192). Greulich et al., were able to prove the 
involvement of the GATA3 pathway in eosinophilic COPD patients through their phase IIa 
clinical trial which sought to demonstrate the feasibility to reduce sputum eosinophilia in 
COPD patients with elevated sputum eosinophil counts through treatment involving the 
inhalation of GATA3-specific DNAzyme SB010 for 4 weeks and were able to conclude that 
a decrease in airway eosinophilia is possible to attain via the GATA3-specific DNAzyme as 
such seen previously in asthmatic patients (191). Furthermore, the trial was able to identify 
the safety aspects associated with the use of SB010 in the studied COPD population whereby 
serious adverse events were not reported (191). However, the trial only included a small 
patient group  so more studies including a larger patient groups and longer treatment period 
will be required for the identification of the long-term clinical effectiveness and safety in this 
subgroup of COPD patients (191). 
 
4.0 Eosinophils and Cystic Fibrosis 
 
Cystic fibrosis is an autosomal recessive disorder that is an illness which is 
chronically progressive and life-limiting (193–196). The disease occurs due to a gene 
mutation of CF transmembrane conductance regulator (CFTR) causing a significant 
functional deficiency in the CFTR protein which are highly expressed in the tissues of the 
airways (193–195). In normal circumstances, the CFTR protein functions to regulate the 
movement of chloride and sodium ions across the epithelial cell membranes but when either 
one or both copies of the gene is mutated, transport of the ions is deficient, resulting in the 
accumulation of thick mucus throughout the body which can lead to the development of 
respiratory insufficiency, consequential deficiencies in host anti-bacterial defences and 
various other systemic obstructions and abnormalities (193–195). Including being a 
chronically progressive lung illness, cystic fibrosis is also characterised by extensive 
inflammation and respiratory failure (195). This could be further exacerbated by the 
formation of biofilms on the exterior of medical appliances utilized for treatment causing life-
threatening infections in these patients (197). Cystic fibrosis is known to affect multiple 
organs and the common symptoms include breathlessness or wheeze, persistent cough along 
with frequent respiratory infections, increased appetite and bulky greasy stools (198). 
Deterioration in pulmonary symptoms and the loss of lung function are the key factors that 
determine the severity of cystic fibrosis. More than half of the patients may require a lung 












Cystic fibrosis associated inflammation is known to be dominated by neutrophils 
which releases oxidants and proteases such as elastase which can be found in airway 
secretions preceding the development of bronchiectasis in these patients (194,195,200,201). 
A few studies have also reported of the correlation between neutrophil elastase with the 
deterioration of lung function as well as respiratory exacerbations (194,200). However, 
Zhang et al., notes that a type II inflammation associated with an asthma phenotype can often 
be recognised in cystic fibrosis patients (195). The presence of this type of inflammation is 
indicated by the increased levels of total immunoglobulin E (IgE), specific IgE sensitization 
or absolute eosinophil count in the circulation independent of infection by the pathogen, 
Pseudomonas aeruginosa (195,202). This enables the differentiation of the similar symptoms 
of asthma and cystic fibrosis in terms of variability of lung function and bronchodilator 
response which in turn aids the recovery of  lung function, airway remodeling, and rate of 
exacerbations in patients with eosinophilic inflammation related exacerbations through the 
focus of treatment on to the type II inflammatory response (195). Moreover, the study by 
Zhang et al., showed positive effects via a decrease in eosinophil and IgE levels as well as 
dose of corticosteroids when mepolizumab was used  to treat type II inflammation in patients 
with eosinophilic phenotype cystic fibrosis (195). 
 
Apart from neutrophils that are known to play an important inflammatory role in 
airway disease associated with cystic fibrosis, eosinophils are also found to be one of the 
components that contribute to injury during cystic fibrosis. In two separate studies involving 
42 and 20 patients with cystic fibrosis respectively, Koller et al., showed significantly higher 
levels of ECP in sputum of patients with cystic fibrosis compared to control subjects 
(203,204). Collectively, these findings indicated the destructive role played by eosinophils 
and an interrelationship between the clinical variables and secretory activity of eosinophils in 
cystic fibrosis. An increase in the propensity of eosinophils to release their granule proteins 
and a firm correlation between ECP levels and variables of pulmonary function like forced 
vital capacity has also been identified (204,205). Furthermore, cytokine profiles were found 
to be responsible for eosinophil activation and degranulation in patients with cystic fibrosis, 
especially IL-8 and IL-3 were found to be significantly correlated with the levels of ECP in 
sputa from 32 patients and therefore, these appeared to be responsible for elevated 















However, the mainstay drugs used to treat cystic fibrosis have been noted to cause 
various side effects (207). Thus, in order to diminish these drug associated side effects 
experienced by patients, tissue targeting strategies should be utilized to overcome the 
inadequate drug penetration due to the barrier formed by the accumulation of thick and 
viscous mucus (208,209).  
 
5.0 Eosinophils and Pneumonia 
 
Pneumonia is a disease which is relatively prevalent and has caused a significant 
burden towards the global population (210). It is defined by the acute infection of the lung 
parenchyma and is used as a hypernym to describe a cluster of syndromes caused by not one 
disease but a group of specific infections, which result in different manifestations and 
sequelae (210,211). Acute and chronic eosinophilic pneumonia are two common pulmonary 
eosinophilic disorders which occur due to lung tissue damage by activated eosinophils 
(212,213). These disorders are characterized by the build-up of eosinophilic infiltrates in the 
pulmonary parenchyma, often accompanied by peripheral blood eosinophilia, which can be 
caused by either infectious or non-infectious factors (212,214). 
De Giacomi et al., reports significantly elevated levels of IL-33 in acute eosinophilic 
pneumonia (AEP) patients and hypothesized that IL-33 plays an essential role in AEP (213). 
This is because attraction and activation of eosinophils is amplified when Th2-polarizing 
cytokines, IL-5 and IL-13 are rapidly produced due to the robust production of IL-33 as well 
as the enlistment and activation of ILC2 cells in the mucosa of the airway which takes place 
due to either epithelial or endothelial cell (213). However, the study by Katoh et. al. reports 
that IL-33 levels were not considerably elevated in the bronchial alveolar lavage fluid 
(BALF) of eosinophilic pneumonia patients whereas IL-25 and IL-5 levels were significantly 
heightened in the BALF of chronic eosinophilic pneumonia (CEP) patients but not AEP 
patients (215). Hence, it was postulated that CEP might be perpetuated by IL-25 which were 
thought to be produced by eosinophils via IL-5 stimulation (215,216). Despite these reports, 
the pathophysiology of both AEP and CEP are poorly understood and will require further 











Treatment of AEP and CEP both utilize corticosteroids as the mainstays of treatment 
in which AEP is treated with systemic corticosteroids whereas CEP utilizes oral 
corticosteroid therapy with an aim to diminish the disease progression as well as lessen the 
risk of relapse (212–214,217–219). As an alternative therapy for CEP, biologic agents have 
been utilized for the regulation of eosinophilic inflammation (218,219). Studies have shown 
the effectiveness of omalizumab, an anti-IgE antibody and anti-IL-5 antibody’s, 
mepolizumab and reslizumab in the treatment of CEP through the reduction or 
discontinuation of corticosteroid use in patients with relapsed CEP (218,219). IL-5 is a 
common aim in the treatment of CEP because its elevated levels are associated with the 
release of cytotoxic granular proteins from eosinophils which is postulated to be an important 
underlying mechanism of CEP (219). However, there is insufficient information supporting 
the utilization of biologics for CEP treatment as well as the concerns associated with the 
adaptation and treatment duration of it (218,219). Hence, further studies regarding the use of 
steroid-sparing therapeutic regimens as an alternative therapy for CEP are required. 
6.0 Eosinophils and Lung Cancer 
 
 Lung cancer is a common malignancy among both sexes and represents over 10% of 
all malignancies (220,221). The occurrence of eosinophilia is often attributed to 
hematological malignancies, with some cases of solid tumour-associated eosinophilia. 
Approximately 1% of malignant tumours are associated eosinophilia (220). Bone marrow 
stimulation by IL-5 is theorized to be the primary causative factor of solid malignancy-
associated eosinophilia. Paraneoplastic eosinophilia cannot be treated with a specific 
treatment, besides treating the underlying malignancy using typical therapies, including 
surgery, chemotherapy, radiotherapy, or even novel treatments such as metformin (222).  
 
6.1 Function of eosinophils in the pathophysiology of lung cancer  
 A distinct feature of cancer is sustained low-grade inflammation. Eosinophils have 
long been associated with cancer as they are one of the regulatory components of the tumour 
microenvironment (TME) responsible for tumour initiation and development (223). 
Eosinophils are commonly associated with negative connotations in allergic diseases, 
however they are able to provide immune protection against helminths, bacterial and viral 
pathogens (223).  
There are evidences showing that the infiltration of eosinophils into tumour cells 











observed in many studies of patients with cancer as well as mouse models of cancer. Studies 
have reported that activated eosinophils play a vital role in tumour rejection. Activated 
tumour-honing eosinophils release chemoattractants which induces the migration of tumour-
specific CD8(+) T-cells into the tumour, resulting in tumour eradication and thus, an 
increased chance of survival (225). Tumour rejection is also promoted by the significant 
alterations in the tumour microenvironment as initiated by the activated eosinophils, such as 
macrophage polarization and normalization of tumour vasculature (225).  
Eosinophil peroxidase (EPO), which is an eosinophilic cationic granule protein, 
drives cell cycle progression and proliferation at non-cytotoxic levels, thus suggesting the 
role of eosinophils in tumorigenesis (226). According to a study conducted by Walsh et al., 
EPO increased the expression and phosphorylation of epidermal growth factor-2 (HER2) in a 
sustained manner, which consequently induced extracellular-regulated kinase 1/2 activation 
(226). Subsequently, cyclin-dependent kinase inhibitor p27 (kip) entered the cytoplasm from 
the nucleus in a focal adhesion kinase-dependent manner. Thus, the findings of the study led 
to the conclusion that EPO can induce the upregulation of cell proliferation via HER2 
mediation.  
However, the actions of eosinophils and eosinophil mediators varies according to the 
cancer type as eosinophils have been linked to improved prognosis in certain neoplasias but 
poor prognosis in others. This is because eosinophils can produce either anti-tumorigenic 
(e.g. TNF-α, IL-18, granzyme, and cationic proteins) or pro-tumorigenic molecules (e.g. pro-
angiogenetic factors) subject to the internal environment (223). Melanoma, oral, gastric, 
colorectal, and prostate cancers are neoplasias in which eosinophils secrete anti-tumorigenic 
factors whereas a poor prognosis is expected from the actions of eosinophils in cervical 
carcinoma and Hodgkin’s lymphoma (223).  
Although there exist evidences for a positive correlation between eosinophils and 
better responses in some patients with melanoma, investigations to study the relationship 
between eosinophils and NSCLC are not frequently conducted. However, a case report 
showed that a patient with metastatic lung adenocarcinoma (AD), a type of non-small cell 
lung cancer (NSCLC), presented with shortness of breath, chest pain and associated 
hypereosinophilia, as defined by an absolute eosinophil count (AEC) of >1500 cells//µL, in 
the absence of primary bone marrow disorder (220). Additionally, a study done by Lou et al., 
reported that a patient with metastatic lung AD presented with asymptomatic 
hypereosinophilia following initiation of nivolumab therapy, which is an anti-programmed 











eosinophil counts transiently decreased, but increased again following re-initiation. The 
patient showed a favourable response throughout the therapy. Thus, eosinophils can act as 
potential peripheral biomarkers of favourable response to immunotherapy in patients with 
lung carcinoma, which warrants further studies of the role of eosinophils in lung carcinoma 
for the development of novel treatment strategies. As such, efforts should be focused on the 
delivery of eosinophil-targeting drugs for lung cancer in the form of nanocarriers in order to 
improve specificity and reduce adverse effects (228,229).  
 
6.2 Eosinophils as biomarkers of lung cancer  
 Eosinophils can be used as a peripheral blood marker for detecting tumour-associated 
protein expression in cancer patients. Tumours cells in primary lung AD express surface 
immune factors such as indoleamine-2,3-dioxygenase-1 (IDO1) and programmed cell death-
ligand-2 (PD-L2) (230). A study showed that AEC, along with absolute monocyte count 
(AMC), could potentially act as a biomarker to predict IDO1 expression in patients with 
resected stage 1 to 3 primary lung AD (230). IDO1 is a tryptophan (Trp) catabolic enzyme 
that catalyzes the transformation of Trp to kynurenine for immunosuppressive functions such 
as activation of myeloid-derived suppressor cells and T-regulatory cells, inhibition of effector 
T and NK cell functions, and promotion of neovascularization of solid tumours (231). 
 Eosinophils can also act as clinical outcome predictors in patients with lung AD. 
Tanizaki et al., reported that NSLC patients administered nivolumab therapy exhibited higher 
AECs which were significantly linked to a better progression-free and overall survival (232). 
Additionally, a cohort study reported that elevated eosinophil counts correlated with reduced 
mortality risk in specific subgroups of cancer patients, such as colorectal cancer (233).   
 However, a study showed that only a small percentage of eosinophils (0.3%) were 
present in the immune infiltrate composition of NSCLC tumours (234).  
 Besides AEC, another eosinophil-related biomarker of lung AD is EPO. Ye et al., 
demonstrated that EPO overexpression in lung AD patients can potentially act as a biomarker 
for poor prognosis (235). During the study, a significantly higher expression of EPO mRNA 
and protein in lung AD tissues as compared to adjacent normal tissues were observed (235). 
Moreover, patients with EPO overexpression were significantly associated with pathologic-
tumour nodes metastases stage and lymph node metastasis, as well as decreased survival time 














7.0 Eosinophils and Acute Lung Injury  
 
 Acute lung injury (ALI) describes clinical syndromes of acute respiratory failure with 
prominent mortality and morbidity rates (236). The management of ALI after exclusion of 
infection consists of primarily supportive measures. Other diagnoses can be ruled out by 
performing surgical lung biopsy, however this measure has proven to be less useful for 
predicting therapy methods and outcomes in ALI (237). Peripheral blood and tissue 
eosinophil counts are often referred to as hallmarks of steroid-responsive acute eosinophilic 
pneumonia, but are not typically associated with ALI (237). Thus, a study conducted by 
Willetts et al. demonstrated that eosinophil peroxidase-recognizing monoclonal antibody 
(EPX-mAb) immunohistochemistry can be used as a method to assess eosinophil 
accumulation or degranulation in the lungs of ALI patients as well as predict the prognosis of 
survival (237). Therefore, it is suggested that EPX-mAb immunohistochemistry can be 
utilized as a diagnostic biomarker to identify a proportion of ALI patients with favourable 
clinical outcomes.  
 
Various clinical trials conducted targeting eosinophils in respiratory diseases are shown in 
Tables 1-3 and various important drugs targeting eosinophils in respiratory diseases are 












Respiratory disorders are chronic conditions requiring long-term therapy to prevent clinical 
symptoms. Morbidity and mortality are high for many respiratory disorders and existing 
available treatments are restricted due to lack of effectiveness, severe toxicity or both. Recent 
efforts to understand eosinophil biology has opened the door to many innovative biological 
treatments. Various drugs that target eosinophils are currently being tested in clinical trials 
and needs to be validated prior to medical use. No health issues are raised till date, despite 
theoretical concerns about the possible toxicity of rapidly declining eosinophil counts and the 
long-term effects of eosinophil depletion on the immune system and tumor monitoring. We 
expect to gain a better understanding with more research to recognize new biological factors 
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Figure 1: Schematic representation of surface receptors and immunological moieties of 
eosinophils. Eosinophils are bi-lobed, multi-functional innate immune cells with diverse cell 
surface receptors, including those crucial for chemotaxis, cell adhesion, activation (via 
cytokine/growth factors), lipid mediation, and immune modulation (CD40/80/86/siglec-
8/Fc/MHC class-II). Eosinophils also comprise of a variety of intracellular functional 
moieties, such as lipid bodies and granules that play a key role in immune regulation and 
eosinophil functionality.  
Abbreviations: PR – Pattern recognition receptors; MBP – Major basic protein; EPX – 
Eosinophil peroxidase; MHC – Major histocompatibility complex; CD – Cluster of 
differentiation; CCR - CC-chemokine receptor; CXCR - CXC-chemokine receptor; FPR - 
Formyl peptide receptor; C5aR - Complement component 5a receptor; C3aR - Complement 
component 3a receptor; LFA-1 - Lymphocyte function-associated antigen 1; CR – 
Complement receptor; LTC4 – Leukotriene C4; LTE4 - Leukotriene E4; Leukotriene D4; 
PAF - Platelet-activating factor; PAR – Protease activated receptor; PAFR - Platelet-
activating factor receptor; CRTH2 - Chemoattractant receptor-homologous molecule 
expressed on T-helper type 2 cells; DP1 - Prostaglandin D2 receptor 1; EP4 - Prostaglandin 
E2 receptor 4; LTB4 - Leukotriene B4 
 
 
Figure 2: Pathophysiology of eosinophils in asthma Abbreviations: IL (Interleukin); 
TSLP (thymic stromal lymphopoietin); APC (Antigen-presenting cell); Th0 (naïve T-cell); 
Th2 (T-helper type 2 cells); MBP (Major basic protein); EPO (Eosinophil peroxidase); ECP 
(Eosinophil cationic protein); EDN (Eosinophil-derived neurotoxin); NGF (Nerve growth 
factor); SCF (Stem cell factor); ASM (Airway smooth muscle); AHR (Airway 
hyperresponsiveness); TGF-  (Transforming growth factor beta); ECM (Extracellular 
matrix)  
 





 T helper 2 cells; IL – Interleukin; PAF – Platelet activating factor; 
MBP – Major basic protein; EPO – Eosinophil peroxidase; ECP – Eosinophil cationic protein 
 
 
Figure 4: Current drugs acting on eosinophils  
Abbreviations: IL (Interleukin); TSLP (thymic stromal lymphopoietin); Th0 (naïve T-cell); 
Th2 (T-helper type 2 cells); ILC2 (Type 2 innate lymphoid cells); IL-5R  (Interleukin-5 
receptor alpha); CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 
cells); PGD2 (Prostaglandin D2); GM-CSF (Granulocyte-macrophage colony-stimulating 
factor); IL-4R   (Interleukin-4 receptor alpha); IgE (Immunoglobulin E); FcɛRI (High-
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Table 2: Clinical trials on eosinophils acting in COPD 
 
S. No Intervention No. of 
recruitments/Country/Phase of 
study/Ongoing/cancelled 




1144/Korea Evaluation of ICS prescription status according to 







2 Benralizumab 29/Finland/Phase II Effect on bacterial load in the airways associated 
with the decline in eosinophilic airway 
inflammation when treated with benralizumab. 
AstraZeneca (284) 
3 Budesonide 1200/USA/Phase III/Completed Establishment of characteristics that determine the 
risk of exacerbation and clinical response to 
treatment with ICS in COPD patients using the 




645/Germany/Completed Comparison of efficacy and safety of treatment 
initiation guided by blood eosinophils with either 
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airways of COPD patients. 
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10 Mepolizumab 19/Canada/Phase III/Completed Determination of mepolizumab’s potential to 
decrease percentage of sputum eosinophil in 
cigarette smoke associated COPD patients with 
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Assessment of mepolizumab’s effects on clinical 
features of cigarette smoke associated COPD 
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Vilanterol Validation of COPD clusters identified in the past. 
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Analysis of losmapimod’s effect as a treatment to 
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eosinophils in the direction of corticosteroid 
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as an add-on therapy to budesonide and double dose of 
budesonide for the suppression of airway eosinophilia and 






15 Allergen Allergic 
rhinitis 
- Determination of eosinophilia in the mucosa, apoptotic 
eosinophils, general cell apoptosis, cell proliferation and CCL5 
and CCL11 expression in allergic airway tissues of humans upon 
resolution of symptomatic eosinophilic inflammation, in vivo. 
- (315) 
16 Montelukast Bronchiolitis 146/Iran/NA/
Completed 
Investigation of montelukast’s effect on degranulation of 
eosinophils and recurrent episodes of wheezing in patients with 























































































































































































































































































































































































































































































































































































































































































































































































































































































































Abbreviations: IV (Intravenous); QOL (Quality of Life); SC (Subcutaneous); ACQ (Asthma 
Control Questionnaire); FcɛRI (High-affinity immunoglobin E receptor); PBE (Peripheral 
blood eosinophil); ICS (Inhaled corticosteroids); AQLQ (Asthma Quality of Life 
Questionnaire); FEV1 (Forced expiratory volume); ADCC (Antibody-dependent cellular 
cytotoxicity); CCR3 (CC-chemokine receptor 3); CCL (CC-chemokine ligand); TGF- 1 
(Transforming growth factor beta 1); BALF (Bronchoalveolar lavage fluid); PGD2 
(Prostaglandin D2); CRTH2 (Chemoattractant receptor-homologous molecule expressed on 
Th2 cells); TSLP (Thymic stromal lymphopoietin); FeNO (Fraction of exhaled nitric oxide); 
ILC2 (Type 2 innate lymphoid cells);  c (Beta chain); OCS (Oral corticosteroid); GM-CSF 
(Granulocyte-macrophage colony-stimulating factor). 
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